Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs MOTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Hepatic via CYP2C9 and glucuronidation; minor via CYP2C8.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Highly protein-bound (approximately 99%) primarily to albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Approximately 0.1-0.2 L/kg (range 0.1-0.2 L/kg); indicative of limited tissue distribution due to high protein binding. Larger Vd in neonates (0.3-0.4 L/kg).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral immediate-release: 80-100%; oral extended-release: approximately 85-90% relative to immediate-release; intravenous: 100%; topical (e.g., gel): 3-8% systemic absorption.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
GFR 30-59 m L/min: use minimum effective dose, monitor renal function; GFR <30 m L/min: avoid use; dialysis: not removed by hemodialysis, avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50%; Class C: avoid use.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Children 6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day, not to exceed adult maximum; for fever >39°C, 10 mg/kg/dose; available as oral suspension (100 mg/5 m L).
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Initiate at the lowest effective dose (e.g., 200-400 mg every 6-8 hours), maximum 3200 mg/day; monitor for GI bleeding and renal impairment; avoid prolonged use due to increased cardiovascular and GI risks.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Increased risk of cardiovascular thrombotic events; risk of serious GI adverse events including bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; avoid in advanced renal disease.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to ibuprofen or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; active GI bleeding; history of recurrent peptic ulcer disease; severe heart failure.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Concurrent alcohol consumption increases risk of GI bleeding and ulceration. Avoid high-sodium foods to minimize fluid retention and potential exacerbation of hypertension. Grapefruit juice may slightly reduce rate of absorption but is not clinically significant.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered safer but avoid prolonged use due to potential for oligohydramnios. Third trimester: Contraindicated after 20 weeks due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal complications including pulmonary hypertension and renal impairment.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Ibuprofen is excreted into breast milk in very small amounts. The M/P ratio is approximately 0.01. The relative infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but avoid high doses or prolonged use.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No dose adjustment is recommended in pregnancy; however, use should be restricted to the lowest effective dose for the shortest duration possible. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce plasma concentrations, but no formal dose adjustment studies exist. Avoid use after 20 weeks gestation.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
For acute pain, use lowest effective dose for shortest duration to minimize GI and renal risks. Administer with food or milk to reduce GI irritation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. Ibuprofen can mask fever, making infection detection difficult. Caution in asthma patients as it may precipitate bronchospasm. Monitor blood pressure in hypertensive patients due to potential for fluid retention.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Take with food or milk to prevent stomach upset.,Do not exceed 1200 mg per day for OTC use (adults) or as directed by your doctor.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult doctor if symptoms persist for more than 10 days (pain) or 3 days (fever).,Do not take with other NSAIDs or pain relievers without consulting your healthcare provider.,Notify your doctor if you have a history of heart disease, high blood pressure, or stomach ulcers.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs MOTRIN, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. MOTRIN is a NSAID Analgesic that works by Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and MOTRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of MOTRIN is: Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and MOTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. MOTRIN is classified as Category C. Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered sa. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.